MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-14-2025
Bio-Path Holdings Operating Expenses 2011-2025 | BPTH
Annual Operating Expenses Bio-Path Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.8 M | 13.9 M | 10.4 M | 10.9 M | 8.69 M | 7.98 M | 9 M | 8.49 M | 5.48 M | 4.54 M | 3.27 M | 2.58 M | 2.37 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 15.8 M | 2.37 M | 7.96 M |
Quarterly Operating Expenses Bio-Path Holdings
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.56 M | 3.24 M | - | 2.63 M | 3.04 M | 3.7 M | - | 3.28 M | 4.24 M | 5.29 M | - | 3.55 M | 3.01 M | 3.36 M | - | 2.07 M | 1.81 M | 2.45 M | - | 2.97 M | 2.04 M | 3.34 M | - | 2.27 M | 2.49 M | 1.52 M | - | 3.08 M | 1.68 M | 1.92 M | - | 2.48 M | 2.32 M | 2 M | 1.68 M | 2.99 M | 1.94 M | 1.87 M | 1.46 M | 1.51 M | 1.13 M | 1.38 M | 1.6 M | 1.15 M | 1.27 M | 510 K | 791 K | 1.39 M | 429 K | 656 K | - | 840 K | 788 K | 523 K | - | 504 K | 464 K | 593 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.29 M | 429 K | 2.08 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
96.2 M | $ 4.71 | 0.86 % | $ 782 M |  Canada |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 1.3 | - | $ 7.09 M |  China |
 |
Aclaris Therapeutics
ACRS
|
92.7 M | $ 3.25 | - | $ 251 M |  USA |
 |
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 94.81 | - | $ 27.2 B | Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 0.28 | - | $ 609 M |  Israel |
 |
Catalyst Biosciences
CBIO
|
176 M | $ 14.09 | - | $ 928 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
338 M | $ 220.42 | - | $ 5 B |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.29 | -3.8 % | $ 7.92 B |  Australia |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Cellectar Biosciences
CLRB
|
15.3 M | $ 3.62 | - | $ 44.2 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
189 M | $ 87.99 | - | $ 9.08 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
190 M | $ 23.62 | - | $ 2.8 B | USA |
 |
BioVie
BIVI
|
18.1 M | $ 1.45 | - | $ 2.14 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
555 M | $ 63.35 | - | $ 7.09 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
141 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Dynavax Technologies Corporation
DVAX
|
137 M | $ 10.8 | - | $ 1.4 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
209 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
168 M | $ 25.27 | - | $ 1.22 B | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
51.6 M | $ 9.56 | 0.74 % | $ 140 M | USA |
 |
Eton Pharmaceuticals
ETON
|
22.3 M | $ 16.7 | - | $ 428 M | USA |
 |
Exelixis
EXEL
|
598 M | $ 40.88 | - | $ 11.9 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
427 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
1.18 B | $ 564.28 | - | $ 42.7 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
53.7 M | $ 2.3 | - | $ 14.4 M | USA |
 |
AstraZeneca PLC
AZN
|
17.6 B | $ 89.83 | - | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
106 M | $ 9.0 | - | $ 1.47 B | Britain |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
32.9 M | $ 1.05 | - | $ 977 K | Israel |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
1.07 B | $ 11.53 | -0.04 % | $ 746 M | USA |
 |
Biogen
BIIB
|
5.39 B | $ 174.1 | - | $ 25.3 B | USA |
 |
GeoVax Labs
GOVX
|
26.7 M | $ 0.37 | - | $ 672 K | USA |